CONTACT:For more information aboutIntercept Pharmaceuticals, please contact:Intercept Pharmaceuticals:Mark Vignolafirstname.lastname@example.orgMedia inquiries: email@example.comInvestor inquiries: firstname.lastname@example.org
NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its second quarter 2017 financial results prior to the NASDAQ market open on Monday, July 31, 2017. Intercept management will conduct a conference call and audio webcast on Monday, July 31, 2017 at 8:30 a.m. Eastern Time to discuss these results. Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks. About Intercept Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.